Objective: This study aimed to systematically appraise the metaanalyses of observational studies on risk factors and peripheral biomarkers for schizophrenia spectrum disorders. Methods: We conducted an umbrella review to capture all metaanalyses and Mendelian randomization studies that examined associations between non-genetic risk factors and schizophrenia spectrum disorders. For each eligible meta-analysis, we estimated the summary effect size estimate, its 95% confidence and prediction intervals and the I 2 metric. Additionally, evidence for small-study effects and excess significance bias was assessed. Results: Overall, we found 41 eligible papers including 98 associations. Sixty-two associations had a nominally significant (P-value <0.05) effect. Seventy-two of the associations exhibited large or very large between-study heterogeneity, while 13 associations had evidence for small-study effects. Excess significance bias was found in 18 associations. Only five factors (childhood adversities, cannabis use, history of obstetric complications, stressful events during adulthood, and serum folate level) showed robust evidence. Conclusion: Despite identifying 98 associations, there is only robust evidence to suggest that cannabis use, exposure to stressful events during childhood and adulthood, history of obstetric complications, and low serum folate level confer a higher risk for developing schizophrenia spectrum disorders. The evidence on peripheral biomarkers for schizophrenia spectrum disorders remains limited. 
Introduction
Schizophrenia is a mental disorder with a median lifetime prevalence of 4.0 per 1000 individuals (1) . Its onset characteristically occurs in adolescence or early adulthood (2) . A diagnosis of schizophrenia is associated with significant disability and with premature all-cause mortality (3, 4) . The death rate is predominantly due to suicide early in the course of the disorder and cardio-metabolic disturbances later in life (1, 4, 5) . Accumulating evidence indicates that a complex interplay of genetic and environmental risk factors probably underpins the emergence of schizophrenia (6) .
Over the past twenty-five years, the field has witnessed an explosion in observational studies investigating putative environmental risk factors. Two previously published field-wide systematic reviews found that few non-genetic risk factors were supported by good quality evidence (7, 8) . These reviews, however, did not provide a quantitative appraisal of epidemiological credibility nor did they explore potential biases (7, 8) .
Aims of the study
In this study, we conducted an umbrella review of meta-analyses on risk factors and peripheral biomarkers for schizophrenia and other psychotic disorders. We assessed the potential for bias in this literature, and we identified associations supported by the most robust epidemiological evidence. The potential causal association between risk factors and schizophrenia was examined by systematically searching for Mendelian randomization (MR) studies, a novel epidemiological study design allowing for better control of reverse causality and confounding (9) .
Methods
This study is an umbrella review, which is a systematic collection and critical evaluation of multiple systematic reviews and meta-analyses on a specific research topic (10) . Similar efforts have been published for other chronic medical conditions. (11) (12) (13) (14) (15) (16) Search strategy and eligibility criteria
We systematically searched PubMed from inception to January 5, 2017 to identify meta-analyses of observational studies examining associations of schizophrenia spectrum disorders in adults and either environmental (i.e., non-genetic) risk factors or peripheral biomarkers. The following search algorithm was used: (schizophrenia OR psychosis) AND ('systematic review*' OR meta-analys*). Peripheral biomarkers were defined as biomarkers measurable in serum/plasma, saliva, or urine. Based on a definition by the World Health Organization (17), a risk factor was defined as any attribute, characteristic or exposure of an individual that increases the likelihood of developing a disease or injury.
We excluded meta-analyses that investigated genetic variants, neuroimaging markers, or cerebrospinal fluid markers. Also, we excluded metaanalyses that examined environmental risk factors for the transition to psychosis in individuals at ultra-high risk, because these factors have been recently examined in a published meta-analysis and study-specific data are not publicly available (18) . We considered as eligible meta-analyses that included at least three independent samples. Language restrictions were not applied. When more than one meta-analysis was available on the same association, we included the one with the largest number of non-overlapping prospective observational studies.
Moreover, we performed an additional search on PubMed to systematically capture MR studies for schizophrenia spectrum disorders using the following search algorithm: 'mendelian randomization' OR 'mendelian randomisation'. An MR study is an epidemiological study design using triangulation methods to address the causal relationship between an exposure and an outcome in observational studies (19) . It is an application of the technique of instrumental variables with genotype acting as an instrument for the exposure of interest. The term 'Mendelian randomization' is a method of using measured variation in genes of known function to examine the effect of an exposure on a disease (20) . We did not include MR studies that used only summary-level data from candidate gene association studies.
Initial title screening was performed by one researcher (LB), and two independent researchers extracted the data (LB and EE). Discrepancies were discussed, and consensus was reached.
Data extraction
From each meta-analysis, we abstracted information on first author, year and journal of publication, examined risk factors, number and study design of component studies, and study-specific risk estimates (i.e., risk ratio, odds ratio, hazard ratio, Cohen's d, or Hedges' g). We additionally recorded whether the eligible meta-analyses performed a qualitative assessment of component studies based on predefined quality scores or scales, such as the Newcastle-Ottawa scale. For each eligible meta-analysis, we examined whether component studies included overlapping samples; in such circumstances, we considered only the component study with the largest sample size.
From each MR study, we extracted the following information: first author, year and journal of publication, sample size, effect size metric, causal effect size estimate along its 95% confidence interval (CI), P-value, study design, and genetic instrument.
Statistical analysis
Measures of standardized mean difference (i.e., Cohen's d and Hedges' g) were transformed to odds ratio. For each meta-analysis, we estimated the summary effect size estimate and its 95% CI, using both fixed-effect and random-effects models (21, 22) . We also estimated the 95% prediction interval, which accounts for between-study heterogeneity and evaluates the uncertainty for the effect that would be expected in a new study addressing that same association (23, 24) . For the largest study of each meta-analysis, we estimated the SE of the effect size to examine whether it was less than 0.10.
Between-study heterogeneity was quantified using the I 2 metric. I 2 ranges between 0% and 100% and quantifies the variability in effect estimates that is due to heterogeneity rather than to sampling error (25) . Values exceeding 50% or 75% are considered to represent large or very large heterogeneity respectively.
We assessed small-study effects using the Egger's regression asymmetry test (26, 27) . A P-value <0.10 combined with a more conservative effect in the largest study than in random-effects meta-analysis was judged to provide adequate evidence for small-study effects. We also applied the excess statistical significance test, which evaluates whether there is a relative excess of statistically significant findings in the published literature (28) . It is a statistical test that assesses whether the observed number of studies with statistically significant results is larger than expected. Excess statistical significance was claimed at two-sided P-value <0.10 (29).
Assessment of epidemiological credibility
To identify associations with robust evidence, we applied a set of methodological criteria, which have been previously applied in other research fields (11) (12) (13) (14) (15) (16) . For evidence to be convincing, >1000 cases were required as well as a highly significant association (P-value <10
À6 by random-effects model), no evidence of small-study effects or excess significance bias, a 95% prediction interval excluding the null value and no large between-study heterogeneity (I 2 < 50%). Highly suggestive evidence required >1000 cases, a highly significant association (P-value <10
À6
by random-effects model) and a statistically significant effect in the largest study. Suggestive evidence required >1000 cases and P-value <0.001 by the random-effects model, whereas the remaining nominally significant risk factors (P-value <0.05) were supported by weak evidence.
For associations with convincing or highly suggestive evidence, to examine the temporal relationship between the exposure and the outcome, we performed a sensitivity analysis synthesizing evidence from prospective cohort studies only. An additional sensitivity analysis was performed for component studies that applied a structured diagnostic interview for case definition.
Results
Overall, we searched 3499 articles and 41 articles fulfilled the eligibility criteria ( Fig. 1) . During fulltext screening, 31 articles were excluded, because a larger meta-analysis examining the same association was available, whereas 28 systematic reviews were excluded because there was no quantitative synthesis of the evidence. The 41 eligible papers examined a total of 98 associations (41 environmental factors and 57 peripheral biomarkers).
Ten of the 41 papers (24%) reported a qualitative assessment of component studies through a standardized tool. Seven of these used the Newcastle-Ottawa scale, and three papers used a scoring system based on the STROBE statement (30) . Six additional papers (15%) used a tailormade assessment tool.
Environmental risk factors
Overall, 41 environmental risk factors were examined for an association with schizophrenia. Eleven associations (stressful events during adulthood, Borna disease virus infection, general academic achievement, handedness, cannabis use, tobacco smoking, traumatic brain injury, obstetric complications, advanced paternal age, childhood adversities, and urbanicity) were studied in at least 1000 cases.
Thirty associations (73%) presented a nominally significant summary effect, 21 associations remained significant at P-value <0.001, but only 167 were articles on other research topics 31 were not the largest meta-analysis 28 were systematic reviews without quantitative synthesis 10 were meta-analyses not presenting study-specific effect estimates 3 were meta-analyses with fundamental statistical errors 2 were meta-analyses including less than 3 component studies 3022 articles were excluded 1288 were treatment studies 539 were articles on other research topics 526 were articles about genetic epidemiology 332 were diagnostic, prognostic or screening studies 241 were editorials or narrative reviews 37 were articles about health economics and quality of life 34 were methodological papers 25 were incidence or prevalence studies 195 articles were excluded 83 were articles on other research topics 49 were diagnostic, prognostic or screening studies 33 were editorials or narrative reviews 16 were treatment studies 8 were incidence or prevalence studies 6 were articles about health economics and quality of life 14 associations achieved a P-value <10 À6 under the random-effects model (Table S1 ). Only four associations (stressful events during adulthood, cannabis use, childhood adversities, and obstetric complications) had a P-value <10 À6 and were studied in at least 1000 cases. Seven associations (23%) were reported in meta-analyses that included a largest study with a SE <0.10 (stressful events during adulthood, general academic achievement, handedness, tobacco smoking, traumatic brain injury, paternal age, and urbanicity). The result of the largest study was more conservative than the summary result in 19 associations (46%).
In twenty associations (49%), small or moderate between-study heterogeneity was found (I 2 < 50%). In 10 meta-analyses (24%), 95% prediction intervals excluded the null value. Five associations (handedness, childhood social withdrawal, Toxoplasma gondii infection, traumatic brain injury, and cooperativeness) were reported in meta-analyses with evidence for small-study effects. Six associations (handedness, childhood social withdrawal, Toxoplasma gondii infection, cooperativeness, openness, and agreeableness) were reported in meta-analyses with evidence for excess significance bias (Table S1 ). The excess statistical significance test was not performed in four associations (parental communication deviance, tobacco smoking, paternal age, and urbanicity), because the study-specific sample sizes were not available and power calculations could not be performed.
Peripheral biomarkers
Fifty-seven associations of peripheral biomarkers and risk for schizophrenia were identified. Twelve associations (21%), pertaining to serum BDNF, serum vitamin B 12 , serum CRP, serum interleukin-6, serum antigliandin IgA and IgG, serum anti-TTG2 IgA, serum leptin, serum folate, serum TNF-a, serum morning cortisol, and plasma adiponectin, were studied in a total sample of more than 1000 cases.
Thirty-two of 57 associations (56%) presented a nominally significant effect, 16 associations remained significant at P-value <0.001, and four of these (serum S100B, serum DPA, serum folate, and plasma TAS) had a P-value <10 À6 (Table S2 ). Only the association of schizophrenia with serum folate level had a P-value <10
À6 and included a total number of cases greater than 1000. Also, only the association with serum TNF-a had largest study with a SE <0.10. The effect of the largest study was more conservative than the summary effect in 35 associations (61%).
Six associations (11%) presented small or moderate between-study heterogeneity (I 2 < 50%), and 42 associations (77%) had an I 2 > 75%. Only the association with impaired glucose tolerance had a 95% prediction interval excluding the null value, but this association was supported by a trivial number of cases. Thirteen associations (23%) rested on evidence suggestive of small-study effects, and 21 associations (37%) showed evidence for excess statistical significance (Table S2 ).
Assessment of epidemiological credibility
By applying a standardized procedure, we found one association supported by convincing evidence (i.e., history of obstetric complications). Also, we identified four associations (4%) supported by highly suggestive evidence. These associations were as follows: exposure to stressful events during adulthood, exposure to childhood adversities, cannabis use, and serum folate level. Seven associations (7%) had suggestive evidence (urbanicity, Borna disease virus infection, advanced paternal age, tobacco smoking, serum interleukin-6, serum BDNF, and serum CRP). The associations supported by convincing, highly suggestive, and suggestive evidence are presented in Table 1 . Fiftyone associations (52%) presented weak evidence for an association with schizophrenia. The remaining associations had a non-significant effect (P-value >0.05).
In the sensitivity analysis that included only prospective cohort studies, the evidence for the association of cannabis use and exposure to childhood adversities with schizophrenia risk remained highly suggestive ( Table 2 ). The association of exposure to stressful events during adulthood, history of obstetric complications, and serum folate level were not studied in any prospective cohort study. In the sensitivity analysis that included only component studies using a structured diagnostic interview, the association of childhood adversities remained highly suggestive, the association of stressful events during adulthood became suggestive only, and the association of obstetric complications became weak (Table 2 ). For cannabis use and serum folate level, fewer than three component studies using a structured diagnostic interview were available.
Mendelian randomization studies in schizophrenia
We identified five MR studies with a total of six MR analyses. These MR studies examined the causal association of cannabis use (31, 32) , serum CRP (33, 34) , and serum vitamin D (35) with risk for schizophrenia (Table 3 ). All MR studies constructed a genetic risk score as an instrumental variable. Three MR studies used summary-level data, one MR study used individual-level data, whereas one MR study used both summary-level and individual-level data. One MR study was based on a trivial number of schizophrenia cases (34), whereas the remaining MR studies included at least 25 000 cases. A significant protective effect was observed for higher serum level of CRP, and a non-significant effect was found for serum level of vitamin D. The MR studies on cannabis use showed conflicting results.
Discussion
We critically appraised almost 100 associations between risk factors and peripheral biomarkers for psychotic disorders in the schizophrenia spectrum. More than two-thirds of the examined associations presented a nominally significant effect, but most of these associations were based on weak evidence due to either a small number of cases or a P-value close to the significance threshold. This is a common phenomenon which has also been observed in previously published umbrella reviews on other chronic conditions (11) (12) (13) (14) (15) . Our analysis indicated that the association of schizophrenia with exposure to physical or psychological adversities during childhood and adulthood and with cannabis use was based on robust evidence and showed a large effect size (i.e., an odds ratio >2). Furthermore, a history of obstetric complications was associated with increased risk for schizophrenia in offspring. Also, serum folate level was lower in patients with schizophrenia than in healthy controls, and this association was also supported by robust evidence. Cannabis use was associated with a very large risk for schizophrenia spectrum disorders with no evidence of bias. Large between-study heterogeneity was observed, but the 95% prediction interval excluded the null value. Several methodological aspects deserve consideration. First, the degree of cannabis exposure across studies varied, whereas available evidence indicates that heavy use may confer a higher risk for psychosis than light use (36) . In addition, the increasing availability of high-potency cannabis and synthetic cannabinoids could modify the magnitude of this association (37) . Cannabis use is associated with motivation and cognitive impairments (38) , where there is evidence indicating more pronounced effects if cannabis use starts in adolescence (38) . Such factors may therefore influence the role of cannabis use as a risk factor for psychosis across studies, but two published MR studies on this association showed conflicting results (31, 32) Exposure to physical and psychological adversities during childhood showed highly suggestive evidence for an increased risk for schizophrenia. This meta-analysis presented a very large heterogeneity estimate, but the 95% prediction interval excluded the null value. Also, this association remained significant in our sensitivity analyses. Exposure to childhood adversities has been linked with later drug use disorders, indicating a possible correlation between the two highly suggestive risk factors (39, 40) .
Furthermore, a history of obstetric complications was associated with an almost twofold increase in risk for schizophrenia in offspring. This meta-analysis presented a highly significant effect, a small between-study heterogeneity, and a 95% prediction interval excluding the null value, whereas evidence for small-study effects and excess significance bias was absent. This finding is aligned with the neurodevelopmental hypothesis for schizophrenia, which supports that risk factors for schizophrenia affect early neurodevelopment during pregnancy (41) .
Traditional risk factors, such as urban environment (42), advanced paternal age (43), a history of traumatic brain injury (44) , and perinatal infections (45), did not present robust evidence as risk factors for schizophrenia spectrum disorders. This observation does not mean that these factors or other factors and exposures that are difficult to be measured should be ignored or ruled out from further research. For example, in the case of urban environment, nearly all the criteria for highly suggestive evidence were fulfilled, but the P-value was slightly larger than 10
À6
. Further well-designed prospective studies may provide convincing evidence for an association with schizophrenia spectrum disorders.
Migration status is also considered a traditional risk factor for schizophrenia, and our literature search captured three meta-analyses that could be considered eligible and examined this association (46) (47) (48) . These studies showed significant associations for migration status; however, we were not able to further evaluate the findings of these metaanalyses as they suffered from fundamental errors in the synthesis of the available data, such as inclusion of studies with overlapping populations. Furthermore, these studies showed very large heterogeneity (I 2 > 75% in all cases) denoting potential problems from systematic biases and accumulation of very heterogeneous populations that did not allow for robust conclusions. Of course, observed heterogeneity may rather point at the necessity to explore underlying sources of variation that may be genuine, especially for findings that have been consistently replicated in the past.
Fifty-seven biomarkers for schizophrenia spectrum disorders have been studied in meta-analyses of observational studies. The identification of robust biomarkers associated with the schizophrenia spectrum could lead to a better understanding of the pathophysiology and at the same time could offer clinicians a valuable tool for diagnosis in the emerging framework of precision psychiatry (49) . However, in most cases, the sample size of component studies was small, or the P-value was close to the nominal significance threshold. Similar findings were observed in umbrella reviews on peripheral biomarkers for depression and bipolar disorder (50, 51) .
Serum folate level was significantly lower in patients with schizophrenia than in healthy controls, and this association was supported by highly suggestive evidence. A field synopsis for genetic associations in schizophrenia has shown strong epidemiological credibility between rs1801131, a polymorphism in the methylene tetrahydrofolate reductase gene, and risk for schizophrenia (52) . However, the evidence for the link between serum folate level and schizophrenia is based on casecontrol studies and there is a lack of prospective cohort studies supporting this association; therefore, results should be interpreted with caution.
Increased serum CRP level presented suggestive evidence for an increased risk for schizophrenia spectrum disorders (53) . In contrast, the available MR study indicated a causal protective effect for elevated levels of serum CRP level (33) . Although there is accumulating evidence that peripheral immune activation could play a pathophysiological role in schizophrenia, the results of the MR study questions whether the observed CRP elevation in schizophrenia is a consequence of illness activity rather than a risk factor for schizophrenia (33) . Previous studies could have been affected by potential biases regarding the causes of elevated CRP level in patients with schizophrenia, such as reverse causality (33) .
Limitations
Our umbrella review has some limitations. We did not conduct a qualitative assessment of component studies as this should be performed in the original systematic reviews and meta-analyses through standardized tools, such as Newcastle-Ottawa scale. However, only a small proportion of eligible meta-analyses included a standardized qualitative assessment of component studies. Also, we considered only associations that have been examined in a meta-analysis, so we did not include potentially important factors such as socioeconomic status. Furthermore, psychotic disorders are a very heterogeneous group of psychiatric conditions, and the combination of studies on various schizophrenia spectrum disorders in the same meta-analysis could be a potential source of between-study heterogeneity. However, it was not feasible to identify the component studies that are focused exclusively on schizophrenia, given that this process is beyond the scope of an umbrella review.
To conclude, our umbrella review found a wide range of risk factors and biomarkers for schizophrenia spectrum disorders. Although the majority of associations were statistically significant at P-value <0.05, only exposure to childhood adversities and cannabis use were supported by robust evidence. The associations of adult stressful events, obstetric complications, and serum folate level with risk for schizophrenia presented convincing or highly suggestive evidence, but these associations were not examined in prospective studies. We have shown that the contribution of environmental factors and biomarkers to the development of psychotic disorders remains incompletely elucidated. Both child maltreatment and cannabis use are potentially modifiable leading to reduced incidence of schizophrenia (54, 55) . Randomized evidence, however, is still needed before establishing a causal association between child maltreatment or cannabis use and schizophrenia spectrum disorders.
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